Late Relapse in Neuroblastoma: Case Report and Review of the Literature


KEBUDİ R., Koc B., Oflaz Sozmen B.

Current pediatric reviews, cilt.21, sa.2, ss.186-191, 2025 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 2
  • Basım Tarihi: 2025
  • Doi Numarası: 10.2174/0115733963255648231024081333
  • Dergi Adı: Current pediatric reviews
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.186-191
  • Anahtar Kelimeler: dinutuximab, ganglioneuroblastoma., ganglioneuroma, late relapse, MIBG, Neuroblastoma
  • İstanbul Üniversitesi Adresli: Evet

Özet

BACKGROUND: Neuroblastoma is the most com mon extra-cranial solid tu mor in children. The survival rate of relapsed/refractory neuroblastoma is dismal. Late recurrence may occur rarely. CASE PRESENTATION: We have, herein, presented a case with stage IV neuroblastoma who relapsed after 11 years and had a subsequent relapse after 15 years from the initial diagnosis, and reviewed cases with late relapsed (after >5 years) neuroblastoma in the literature. The case presented with recurrent disease at the T7 vertebra after 11 years from the initial diagnosis. The patient received surgery, che motherapy, MIBG treatment, and antiGD2 combined with che motherapy, and had a further local recurrence in the paravertebral area of the re moved T7 vertebra after three years. The patient was operated, received anti-GD2 combined with che motherapy, and is still alive with no symptoms for 19 months after the last relapse. CONCLUSION: There is not a well-established treatment regimen for the majority of these patients. MIBG treatment and antiGD2 combined with che motherapy may be promising options for relapsed/ refractory neuroblastoma.